Disease: Candida glabrata infection

Anticancer drugs targeting topoisomerase II for antifungal treatment

Researchers found that several anticancer drugs commonly used to treat human cancers can also effectively kill fungal infections, especially resistant strains of Candida. The most promising drug, idarubicin, works by targeting an essential enzyme in fungi called topoisomerase II, causing DNA damage and cell death. This discovery suggests a new strategy for treating serious fungal infections by repurposing existing cancer medications, particularly for patients with drug-resistant infections.

Read More »

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Read More »
Scroll to Top